Clinical trials: Genetic Mutation
Breast Cancer
The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers
Women with a BRCA1 mutation face a lifetime risk of breast cancer of approximately 70% and a lifetime risk of ovarian cancer of approximately 40%.
- Trial name
- NCT01022333
- Testing
- Diindolylmethane (DIM)
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Women's College Hospital
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory).
- Conditions
- Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation
- Trial name
- NCT03683433
- Testing
- Azacitidine, Enasidenib Mesylate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer
Psychosexual Consequences of Risk-reducing Salpingo-oophorectomy
Short Rationale: Risk-reducing salpingo-oophorectomy (RRSO) is a mainstay in preventing ovarian cancer in BRCA1/2 mutation carriers, as ovarian cancer screening is ineffective in detecting ovarian cancer in an early and curable…
- Trial name
- PURSUE (NCT02372864)
- Testing
- Mindfulness based stress reduction (MBSR)
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- University Medical Center Groningen
PFS
Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC
To compare the efficacy and safety of gefitinib combined with bevacizumab and gefitinib in the treatment of L858R positive mutation in exon 21 of EGFR gene in advanced NSCLC.
- Trial name
- NCT04425187
- Testing
- Gefitinib, Bevacizumab Combined With Gefitinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Acute Myeloid Leukemia, IDH1 Gene Mutation
a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
This is a single arm, open-label, multicenter clinical trial to evaluate the efficacy and safety of ivosidenib+venetoclax+ azacitidine in adult Chinese subjects with newly diagnosed IDH1m AML.A total of approximately 42 China…
- Conditions
- Acute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib
- Trial name
- NCT07007949
- Testing
- Ivosidenib combined with venetoclax and azacitidine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Solid Tumor, Adult, BRCA1 Mutation
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.
- Conditions
- Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
- Trial name
- NCT06380660
- Testing
- ACE-86225106 tablet
- Where
- 14 sites in China
- Volunteers
- 298 people
- Sponsor
- Acerand Therapeutics (Shanghai) Limited
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
This phase I trial studies the side effects and best dose of BSB-2002 when given after cyclophosphamide and fludarabine and tests how well it works in treating NPM1-mutated acute myeloid leukemia (AML) that has come back after a…
- Trial name
- NCT07583303
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- City of Hope Medical Center
Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant
A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene
A double-blind, randomized, intra-subject placebo-controlled, multicenter, multiple dose study, evaluating safety, proof of mechanism, preliminary efficacy and systemic exposure in subjects with confirmed DDEB or RDEB diagnosis…
- Trial name
- NCT03605069
- Testing
- QR-313
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 2 people
- Sponsor
- Phoenicis Therapeutics
Advanced or Metastatic Solid Tumor
The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
This is a phase 1, open-label, single-arm study in Chinese patients with unresectable, locally advanced or metastatic solid tumor with KRAS G12C mutation, for which treatment with curative intent is not available.
- Trial name
- NCT05263986
- Testing
- MRTX849
- Where
- 8 sites in China
- Volunteers
- 22 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Advanced Solid Tumors
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.
- Trial name
- NTS071 (NCT07060989)
- Testing
- NTS071
- Where
- 10 sites in United States, China
- Volunteers
- 220 people
- Sponsor
- Nutshell Therapeutics (Shanghai) Co., LTD.
Metastatic Colorectal Cancer, BRAF V600E Mutation Positive
A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
The study will be conducted in patients with metastatic colorectal cancer (mCRC) harboring a BRAFV600E mutation, to collect clinical data and biological samples to be used for research but also to gather real-world clinical data…
- Trial name
- COBRAF (NCT05639413)
- Testing
- Collection of blood samples
- Where
- 45 sites in France
- Volunteers
- 400 people
- Sponsor
- UNICANCER
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Bladder Cancer, Melanoma
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
The purpose of this study is to investigate the characteristics of tumors in patients treated with nivolumab and to identify features that help to predict a good or bad response to this drug.
- Trial name
- NCT02553642
- Testing
- Nivolumab, Nivolumab plus Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Melanoma Stage IV
Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib
The purpose of this study is to evaluate the activity of Vemurafenib in combination with Fotemustine in Patients with unresectable Stage IV melanoma harboring V600 BRAF mutation who recurred while in treatment with Vemurafenib.
- Trial name
- BeyPro1 (NCT01983124)
- Testing
- Fotemustine + Vemurafenib
- Where
- 2 sites in Italy
- Volunteers
- 31 people
- Sponsor
- Paola Queirolo
Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies
Single Ascending Dose Study in Participants With LCA10
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of EDIT-101 administered via subretinal injection in participants with LCA10 caused by a homozygous or compound…
- Conditions
- Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary, Retinal Disease
- Trial name
- NCT03872479
- Testing
- EDIT-101
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Editas Medicine, Inc.
Dentatorubral-Pallidoluysian Atrophy
Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with dentatorubral-pallidoluysian atrophy (DRPLA) due to a heterozygous pathogenic CAG trinucleotide…
- Trial name
- NCT06706388
- Testing
- nL-ATN1-002
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- n-Lorem Foundation
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations
TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of TAS-117 in patients with advanced or metastatic solid tumors (excluding primary brain tumors)…
- Trial name
- NCT04770246
- Testing
- TAS-117
- Where
- 8 sites in United States, Austria and 2 more
- Volunteers
- 17 people
- Sponsor
- Taiho Oncology, Inc.
Breast Cancer
Adherence to Intensive Surveillance for Hereditary Breast Cancer
Women with strong family histories of breast cancer are at increased risk to have breast cancer. Women whose close relatives have had breast cancer often have more breast cancer screening than other women their age.
- Trial name
- NCT00582803
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HIV-1-infection, HIV Infections
Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV
This study is a phase II, multicenter, randomized, blind, placebo-controlled to evaluate the safety, tolerance, efficacy of ASC22 injection in combination with anti-retroviral therapy to treat subjects living with human…
- Conditions
- HIV-1-infection, HIV Infections, PD-L1 Gene Mutation
- Trial name
- NCT05330143
- Testing
- ASC22 1mg/kg, ASC22 2.5mg/kg, Antiretroviral Therapy
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Gene Mutations, Pseudoxanthoma Elasticum
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
The purpose of this study (Study INZ701-304 [ADAPT]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to…
- Conditions
- Gene Mutations, Pseudoxanthoma Elasticum, Arterial Calcification, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
- Trial name
- NCT06462547
- Testing
- INZ-701
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 22 people
- Sponsor
- Inozyme Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.